While they were the stars early in the market’s rebound—the iShares Nasdaq Biotechnology exchange-traded fund (ticker: IBB) surged 37% from March 23 through May 11—they have gone nowhere for the past six weeks.That has been a boon for companies like Moderna (MRNA) and Novavax (NVAX), helping biotechs demonstrate that their platforms, whose value had been largely theoretical, might be worth something.